TScan Therapeutics, Inc. (TCRX) has recently received a “Neutral” rating from analyst Andres Y. Maldonado at HC Wainwright & Co., a noteworthy event for both current and prospective investors. The rating comes alongside a price target of $7, suggesting a significant potential upside from the stock’s current price of $0.3915. This development underscores the mixed sentiments surrounding TScan’s trajectory as it navigates the complexities of the biotechnology sector.
Market / Price Action
In recent trading sessions, TCRX has experienced notable volatility, reflecting the cautious stance of investors. Currently priced at $0.3915, the stock has undergone a weekly decline of approximately 9.45%, a change of $-0.037. Throughout the past week, the stock has traded with an average volume of around 1,016,241 shares, significantly surpassing its average volume of 734,060. The current market capitalization sits at $21.65 million, and with a beta of 1.069, TCRX demonstrates a level of volatility consistent with broader market movements. Over the past year, TCRX has faced considerable pressure, with its price oscillating between a 52-week high of $25.79 and a low of $0.3915, pointing to a challenging environment for the company.
[chart type=’price’ value=’TCRX’]
Short- and Long-Term Performance
The performance metrics for TScan Therapeutics reveal a stark contrast between short-term gains and long-term struggles. Over the last 30 days, the stock has appreciated by 20.61%, indicating potential interest or recovery signals among investors. However, this is starkly eclipsed by its quarterly performance, which shows a precipitous decline of 54.84%. Similarly, the 12-month performance is concerning, with a drop of 54.47%. The stock’s volatility metrics reveal fluctuations, with a weekly volatility of 6.56% and a monthly volatility of 7.21%, suggesting that TCRX is experiencing significant price swings relative to its recent trading history.
[chart type=’performance’ value=’TCRX’]
Earnings / Financials
Turning to TScan’s earnings, the recent results tell a mixed story. For the period ending August 12, 2026, the reported earnings per share (EPS) of -$0.23 slightly outperformed analysts’ expectations of -$0.25338, producing a surprise factor of approximately 9.23%. This positive surprise can be seen as a minor win in an otherwise challenging landscape for the biotech firm. In comparison, the previous EPS of -$0.22 had also exceeded estimates, reflecting perhaps an underlying operational resilience despite considerable losses.
[chart type=’income-bar-chart’ value=’TCRX’]
Analyst / Consensus View
The consensus among analysts regarding TCRX’s stock remains cautious. With a total of four ratings, the breakdown includes two “Buy” and two “Hold” recommendations, with no “Sell” ratings reported. The average price target from these analysts is set at $5.75, while the high target matches HC Wainwright’s assessment at $7. This indicates that while there is optimistic potential according to some analysts, the consensus remains tempered, reflecting the company’s volatile scenarios and associated risks.
[chart type=’analyst-ratings’ value=’TCRX’]
Stock Grading or Fundamental View
TScan Therapeutics’ Stocks Telegraph grading score stands at 36, reflecting a composite of the company’s financial health, operational metrics, and market sentiment. This score suggests that while TCRX holds some promise, particularly in innovation and potential revenue streams, the company may not yet exhibit strong fundamentals that typically characterize more attractive investment opportunities. Investors often look for higher scores in stocks that signal robust potential for long-term growth.
[chart type=’st-cards’ value=’TCRX’]
Conclusion
In summary, TScan Therapeutics, while currently rated neutral by leading analysts, merits close attention from investors willing to navigate its high risk-reward dynamics. The significant upside potential indicated by the price target of $7 compared to the current price may appeal to growth-oriented investors or those with a higher risk tolerance. However, the company faces substantial headwinds, evident from its historical performance metrics and ongoing market volatility. Investors should weigh the potential risks against the uncertain outlook, monitoring company developments closely as they consider whether to deepen their exposure to TCRX.